NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_ER_AUC_viability,"Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,81.04899793637586,4.052449896818793,82.60123140617982,1.916986521762544,5.860768439731081,66.61075414733459,percent_activity,2,20,"[""Only highest conc above baseline, active""]",1.8563969051320957,1.8472929324726428,1.7976893763982003,20,cell cycle
APR_HepG2_MitoMembPot_24h_dn,"Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,4.04597444526065,4.870279952753077,88.26991766824456,1.94581272150924,0.0830747818300165,3.37164537110309,log2_fold_induction,2.30102999566398,0.830747818300165,,1.60079318989482,1.25146677949306,1.38564841376053,20,cell morphology
APR_HepG2_MitoMembPot_72h_dn,"Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,3.26802533016381,4.485016052741713,105.44894513154284,2.02304223959147,0.0728654098833392,2.72335444181685,log2_fold_induction,2.30102999566398,0.728654098833392,,1.79730284573467,1.54651404941165,1.62575668905888,20,cell morphology
ATG_Ahr_CIS_up,"Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ahr_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001612.1,AHR,aryl hydrocarbon receptor,https://www.ncbi.nlm.nih.gov/gene/196,"[131,21,57,310,41,150,57,131,21,41,150,310]",[165],Active,5.030241336353182,5.077580942194977,1.6642049561144665,0.22120681103415268,0.19813534805724511,5.093087390444217,log2_fold_induction,2.30102999566398,0.9906767402862255,,-0.35504031568206335,-0.6028421476779897,-0.6796404536425145,20,dna binding
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1","FOS | JUN","FBJ murine osteosarcoma viral oncogene homolog , jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/2353 , https://www.ncbi.nlm.nih.gov/gene/3725",,,Active,1.16963389329704,1.9500588649122472,12.705470066870484,1.1039907373652538,0.11995882938125292,0.9746949110883865,log2_fold_induction,2.30102999566398,0.5997941469062646,"[""Hit-call potentially confounded by overfitting""]",1.1525432894230057,0.3354210736772276,-0.9783454800131701,20,dna binding
ATG_BRE_CIS_up,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.",NP_005891.1,SMAD1,SMAD family member 1,https://www.ncbi.nlm.nih.gov/gene/4086,,,Active,1.7680096183813219,1.9305301618386168,8.823281613774089,0.9456301408788126,0.183163117917566,1.6716168829753402,log2_fold_induction,1.84509804001426,0.91581558958783,,0.9780664868675438,0.5868506457370803,-0.044219245843726385,20,dna binding
ATG_CRE_CIS_up,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006359.3,CREB3,cAMP responsive element binding protein 3,https://www.ncbi.nlm.nih.gov/gene/10488,,,Active,0.7811824898385284,1.069319909663311,83.6140520077309,1.9222792702211215,0.14610828486013952,0.7804531319349515,log2_fold_induction,2.30102999566398,0.7305414243006976,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active""]",2.067172114526932,1.935614562760771,1.8029988801326897,20,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.6315831149199893,1.4763412338218536,134.74909058562048,2.12952584283852,0.22103062321117403,1.3596525960024162,log2_fold_induction,2.30102999566398,1.10515311605587,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",2.2086160760344953,2.089125912959184,1.895202583144101,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.5874500670485248,3.1415336669140537,54.537738135095275,1.7366971223145105,0.10106210757931403,1.3228750558933948,log2_fold_induction,2.30102999566398,0.5053105378965701,,1.30375170821759,0.9159763616376003,0.487517182958078,20,nuclear receptor
ATG_GLI_CIS_up,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005260.1,GLI1,GLI family zinc finger 1,https://www.ncbi.nlm.nih.gov/gene/2735,,,Active,0.531961614992462,1.3837728653165453,2.114303416369925,0.32516731154267015,0.07688568381788191,0.44330135149756805,log2_fold_induction,0.845098040014257,0.38442841908940956,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",0.3983319691733232,0.30475512964182966,0.15730843538069422,20,dna binding
ATG_ISRE_CIS_up,"Data from the assay component ATG_ISRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ISRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene IRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is interferon regulatory factors.",NP_002189.1,IRF1,interferon regulatory factor 1,https://www.ncbi.nlm.nih.gov/gene/3659,,,Active,1.3982492857743303,1.9776553473100393,50.2103595137396,1.7007933309994077,0.14140474857524557,1.1652077382502213,log2_fold_induction,2.30102999566398,0.7070237428762278,,1.7100029569357527,1.362042343798961,0.8053358657155969,20,dna binding
ATG_NFI_CIS_up,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.",NP_001128145.1,NFIA,nuclear factor I/A,https://www.ncbi.nlm.nih.gov/gene/4774,,,Active,0.5515326419635445,1.309184268012936,163.67495286318828,2.21398222452142,0.08425592262892893,0.4596105353661075,log2_fold_induction,2.30102999566398,0.4212796131446447,"[""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",2.2777157606354326,2.204904718837138,2.0946818639414637,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,3.2592819038294176,4.196922858512394,61.32266294897512,1.78762100591708,0.15531769411576343,2.7160682532729403,log2_fold_induction,2.30102999566398,0.7765884705788172,,1.3250919004705626,1.0748749996092952,0.9131672422138457,20,dna binding
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3,POU2F1,POU class 2 homeobox 1,https://www.ncbi.nlm.nih.gov/gene/5451,,,Active,1.2104956767174153,1.7862082475036842,64.20230767438521,1.8075506385398765,0.13553802345377633,1.164331604634611,log2_fold_induction,2.30102999566398,0.6776901172688816,"[""Hit-call potentially confounded by overfitting""]",1.8442152251187705,1.7036561043881437,1.4726272062883452,20,dna binding
ATG_PPARa_TRANS_up,"Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_005027.2,PPARA,peroxisome proliferator-activated receptor alpha,https://www.ncbi.nlm.nih.gov/gene/5465,"[51,18,318,6,36,61,58,37,166,37,6,318,51,18,166,36,61,58]",,Active,1.7105038152588063,1.4782584814278212,46.45675071770116,1.6670488310621372,0.23142147827985585,1.4254198462211805,log2_fold_induction,2.30102999566398,1.1571073913992793,,2.0157746908219227,1.4869135522538157,0.6282406145137509,20,nuclear receptor
ATG_PPARd_TRANS_dn,ATG_PPARd_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_006229.1,PPARD,peroxisome proliferator-activated receptor delta,https://www.ncbi.nlm.nih.gov/gene/5467,,,Active,1.6242081743015264,1.4805961110899934,0.10472292012011329,-0.9799582563124358,0.2193992219938776,1.3535068120823956,log2_fold_induction,-0.522878745280338,1.096996109969388,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",-0.9399189481097528,-1.000923549347937,-1.1000237462897933,20,nuclear receptor
ATG_PPARg_TRANS_up,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,"[72,36,58,34,163,34,36,58,72,163]",,Active,4.41607328841855,3.848546547524059,7.6089505903047145,0.881324763962861,0.2294930428350727,4.456591210819626,log2_fold_induction,1.84509804001426,1.1474652141753636,,0.5007230893019732,0.26722135331962804,0.08245176142847921,20,nuclear receptor
ATG_PPRE_CIS_up,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_005027.2|NP_006229.1|NP_056953.2","PPARA | PPARD | PPARG","peroxisome proliferator-activated receptor alpha , peroxisome proliferator-activated receptor delta , peroxisome proliferator-activated receptor gamma","https://www.ncbi.nlm.nih.gov/gene/5465 , https://www.ncbi.nlm.nih.gov/gene/5467 , https://www.ncbi.nlm.nih.gov/gene/5468",,,Active,3.133219670784918,3.4992984422222917,29.141327344476796,1.4645093293575555,0.1790770191521653,2.6110163923691148,log2_fold_induction,2.30102999566398,0.8953850957608266,,0.9282090815766606,0.542215117382076,0.17809106317852774,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,2.8614797005883914,4.293904618028004,67.95762479292657,1.8322381913071908,0.13328100901796647,2.6064042229672655,log2_fold_induction,2.30102999566398,0.6664050450898323,,1.591978139607477,1.4659227698019492,1.389391996821884,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,1.99336879800087,1.547588173601608,32.27676401045164,1.5088899869282362,0.2576097222766731,1.817983006133457,log2_fold_induction,2.30102999566398,1.2880486113833656,,1.7210113349574903,1.3479263695243042,0.7349716173800735,20,nuclear receptor
ATG_RORE_CIS_up,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.","NP_599023.1|NP_008845.2|NP_005051.2","RORA | RORB | RORC","RAR-related orphan receptor A , RAR-related orphan receptor B , RAR-related orphan receptor C","https://www.ncbi.nlm.nih.gov/gene/6095 , https://www.ncbi.nlm.nih.gov/gene/6096 , https://www.ncbi.nlm.nih.gov/gene/6097",,,Active,1.0927454641467444,1.5960060294711467,1.9159887250702827,0.2823929490775112,0.13693500450105905,0.93069547724166,log2_fold_induction,1.84509804001426,0.6846750225052953,"[""Hit-call potentially confounded by overfitting""]",1.0315574380484471,-0.45130944122731487,-2.8984154153874773,20,nuclear receptor
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2,SP1,Sp1 transcription factor,https://www.ncbi.nlm.nih.gov/gene/6667,"[148,148]",,Active,1.1300225222386424,2.1507990894399445,51.39300518541533,1.7109040136237523,0.10507931938290839,0.9416854352096027,log2_fold_induction,2.30102999566398,0.525396596914542,,1.654624668014109,1.3304117186259419,0.8305011325494499,20,dna binding
ATG_SREBP_CIS_up,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_004167.3,SREBF1,sterol regulatory element binding transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/6720,"[62,61,58,34,34,62,61,58]",,Active,1.0599117601751264,2.9171176218267654,55.094143133264055,1.7411054329697384,0.07266842805682862,0.8832598002943517,log2_fold_induction,2.30102999566398,0.3633421402841431,,1.4245190912011627,1.0838520198840234,0.6722872074459778,20,dna binding
ATG_STAT3_CIS_up,"Data from the assay component ATG_STAT3_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_STAT3_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene STAT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.",NP_644805.1,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),https://www.ncbi.nlm.nih.gov/gene/6774,,,Active,0.9339547005259325,2.1295056200951588,64.60040773031257,1.8102352590858897,0.08771563612818246,0.9338251606852668,log2_fold_induction,2.30102999566398,0.4385781806409123,,1.803624209492276,1.7594352802036295,1.6909549441369123,20,dna binding
BSK_4H_Eotaxin3_down,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_006063.1,CCL26,chemokine (C-C motif) ligand 26,https://www.ncbi.nlm.nih.gov/gene/10344,,,Active,0.12761582398928328,1.569101068722175,39.99999999999999,1.6020599913279623,0.027110177186399995,0.09916065,log10_fold_induction,1.60205999132796,0.08133053155919999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,-1.330098994417842,20,cytokine
BSK_CASM3C_MCSF_down,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3,CSF1,colony stimulating factor 1 (macrophage),https://www.ncbi.nlm.nih.gov/gene/1435,,,Active,0.20379806399775502,2.1083548698940406,39.99999999999999,1.6020599913279623,0.03222070865265,0.1444296075,log10_fold_induction,1.60205999132796,0.09666212595794998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,-0.03673827494738635,20,cytokine
BSK_CASM3C_Thrombomodulin_up,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000352.1,THBD,thrombomodulin,https://www.ncbi.nlm.nih.gov/gene/7056,,,Active,0.1485825782281821,1.4816096488047392,39.99999999999999,1.6020599913279623,0.0334281881304,0.133624492,log10_fold_induction,1.60205999132796,0.10028456439120001,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.13614939456848008,20,gpcr
BSK_hDFCGF_CollagenIII_down,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",NP_000081.1,COL3A1,"collagen, type III, alpha 1",https://www.ncbi.nlm.nih.gov/gene/1281,,,Active,0.3497642757543516,2.471070927164947,40.000000000000014,1.6020599913279625,0.047181200117099996,0.26450262,log10_fold_induction,1.60205999132796,0.14154360035129998,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,-0.49407634299073244,20,cell adhesion molecules
BSK_hDFCGF_MCSF_down,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3,CSF1,colony stimulating factor 1 (macrophage),https://www.ncbi.nlm.nih.gov/gene/1435,,,Active,0.16300413078820114,1.5244284828694465,40.000000000000014,1.6020599913279625,0.0356426758443,0.13230995,log10_fold_induction,1.60205999132796,0.10692802753289998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.403467188998507,20,cytokine
BSK_LPS_PGE2_down,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000947.2,PTGER2,"prostaglandin E receptor 2 (subtype EP2), 53kDa",https://www.ncbi.nlm.nih.gov/gene/5732,,,Active,0.2688214247845464,1.9069484986163752,40.000000000000014,1.6020599913279625,0.04698980683529999,0.23625774500000002,log10_fold_induction,1.60205999132796,0.14096942050589997,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.32635559378854007,20,gpcr
BSK_LPS_TissueFactor_up,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1,F3,"coagulation factor III (thromboplastin, tissue factor)",https://www.ncbi.nlm.nih.gov/gene/2152,,,Active,0.16895039992542885,1.3939214050567468,40.000000000000014,1.6020599913279625,0.0404017039776,0.1378533,log10_fold_induction,1.60205999132796,0.1212051119328,"[""Borderline active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,-1.9392135805698938,20,cytokine
BSK_SAg_Eselectin_up,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.12523279015815403,1.091291811181616,10,1,0.038252154885,0.139788485,log10_fold_induction,1,0.114756464655,"[""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1,1,-1.2259879998286969,20,cell adhesion molecules
CCTE_GLTED_hDIO1_dn,"Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.",,DIO1,iodothyronine deiodinase 1,https://www.ncbi.nlm.nih.gov/gene/1733,,,Active,95.10273363033235,4.755136681516618,23.27791728113532,1.3669441205752164,5.074688733372146,88.15433768,percent_activity,2.30102999566398,20,,0.8336038421776331,0.6987670583811498,0.48126162853716614,20,deiodinase
CCTE_GLTED_hDIO2_dn,"Data from the assay component CCTE_GLTED_hDIO2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO2_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 2'.",,DIO2,iodothyronine deiodinase 2,https://www.ncbi.nlm.nih.gov/gene/1734,,,Active,84.78646506155452,4.2393232530777265,53.4682012939224,1.7280955743890365,4.347339401816814,65.25096525,percent_activity,2.30102999566398,20,,1.1436228298440272,0.8802840304998971,0.6354830702745249,20,deiodinase
CCTE_GLTED_hDIO3_dn,"Data from the assay component CCTE_GLTED_hDIO3 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO3_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.",,DIO3,iodothyronine deiodinase 3,https://www.ncbi.nlm.nih.gov/gene/1735,,,Active,81.22072819705966,4.061036409852983,88.1623710245296,1.9452832615102387,4.524033444680399,67.42964908,percent_activity,2.30102999566398,20,,1.6509160302865789,1.52262961262681,1.3671479675318299,20,deiodinase
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,117.574253075957,5.87871265379785,34.57244046096244,1.53873003737637,1.53481347591287,97.7929675428241,percent_activity,1.90308998699194,20,,1.16789900147335,0.78996977025989,1.02462275210186,20,malformation
CCTE_Simmons_AUR_TPO_dn,"Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",P14650.1,Tpo,thyroid peroxidase,https://www.ncbi.nlm.nih.gov/gene/54314,,,Active,99.4657384813667,4.973286924068335,0.3619523796957283,-0.441348563709311,5.55295187687267,97.015481317658,percent_activity,1.95424250943932,20,,-1.36814347038298,-1.51860762297585,-1.91741833544284,20,oxidoreductase
CEETOX_H295R_ANDR_dn,"Data from the assay component CEETOX_H295R_ANDR was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ANDR_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.22095554514358,1.619744303785906,34.86785617197483,1.54242524587602,0.125632539890173,1.22072595369804,log2_fold_induction,2,0.753795239341038,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56839867836065,1.49865663792297,1.42314493011023,100,steroid hormone
CEETOX_H295R_OHPREG_dn,"Data from the assay component CEETOX_H295R_OHPREG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPREG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,1.02123231108717,1.3237558803657095,56.31390684923843,1.75061565812077,0.12857762349216,1.01096191927738,log2_fold_induction,2,0.77146574095296,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81190069132272,1.72348453819791,1.63121407965884,100,steroid hormone
CEETOX_H295R_OHPROG_dn,"Data from the assay component CEETOX_H295R_OHPROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPROG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,1.50753093217402,1.666382922100781,36.47668268307982,1.56201533519525,0.150778762810161,1.50705789043928,log2_fold_induction,2,0.904672576860966,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.58404985303231,1.51603144138948,1.44273502067313,100,steroid hormone
CEETOX_H295R_TESTO_dn,"Data from the assay component CEETOX_H295R_TESTO was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_TESTO_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Testosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.10693329476374,1.109387737752629,34.91161501615386,1.54296993980187,0.166297928291831,1.10668984345924,log2_fold_induction,2,0.997787569750986,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.66309886461413,1.53222947603036,1.42368962124649,100,steroid hormone
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1543,"[57,57]",,Active,8.36944485597627,9.293386934966808,9.812080506911089,0.991761102881658,0.300193564683644,7.57236596839144,log2_fold_induction,2,0.900580694050932,,0.0207929299301386,0.0207929299301386,-0.0167366726636102,20,cyp
LTEA_HepaRG_CYP1A2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000752.2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",https://www.ncbi.nlm.nih.gov/gene/1544,"[131,131]",,Active,7.66022825738868,8.06770534925506,13.629176184642873,1.13446960570434,0.316497604782422,6.40177478485246,log2_fold_induction,2,0.949492814347266,,0.114419975510322,0.114419975510322,-0.0116500625658267,20,cyp
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4,FASN,fatty acid synthase,https://www.ncbi.nlm.nih.gov/gene/2194,"[58,34,34,58]",,Active,0.382632361692498,1.0410753964301818,17.455675820931766,1.24193666779469,0.122511895873739,0.384456519865586,log2_fold_induction,2,0.367535687621217,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",2.02085459011673,2.02085459011673,0.705823846033625,20,lyase
LTEA_HepaRG_LIPC_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000227.2,LIPC,"lipase, hepatic",https://www.ncbi.nlm.nih.gov/gene/3990,,,Active,0.788156155245521,1.5161071495028848,18.944084671792083,1.27747362615399,0.173285060031091,0.619102287609856,log2_fold_induction,2,0.519855180093273,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.87967187831754,1.87967187831754,-0.722954285283197,20,esterase
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1,THRSP,thyroid hormone responsive,https://www.ncbi.nlm.nih.gov/gene/7069,,,Active,1.4191034791351,1.460249730182738,17.211296760120614,1.23581359284635,0.323940818661091,1.10044365146959,log2_fold_induction,2,0.971822455983273,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.85239730214736,1.85239730214736,-0.510059143653263,20,growth factor
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",https://www.ncbi.nlm.nih.gov/gene/54658,,,Active,0.84472600319188,1.2753730442147846,23.718381906395404,1.37508505766467,0.220778803248623,0.78754509864115,log2_fold_induction,2,0.662336409745869,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.69554437684002,1.69554437684002,0.829097549980373,20,transferase
NVS_ADME_hCYP1A1,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000490.1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1543,"[57,57]",,Active,57.2809865190034,2.86404932595017,0.16351371850125312,-0.786445804964184,1.8911470059282,47.7342141956046,percent_activity,-0.698970004336019,20,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",-0.820252980103433,-0.906304137795213,-0.905726118981605,20,cyp
NVS_ADME_hCYP2A6,"Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2A6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000753.3,CYP2A6,"cytochrome P450, family 2, subfamily A, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1548,,,Active,41.4272265048524,2.07136132524262,5.797166255443731,0.763215755569397,2.29225074962519,34.5226887591791,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.738574726581429,0.186147272092171,-0.022244724948112,20,cyp
NVS_ADME_hCYP2B6,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,79.2143292063207,3.9607164603160347,1.213540262706363,0.0840541898819004,1.55763530034319,75.9462583068477,percent_activity,1.30102999566398,20,,-0.333198567871027,-0.980603099787762,-0.760585195162388,20,cyp
NVS_ADME_hCYP2C19,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,83.6423613306189,4.182118066530945,1.692654409616395,0.228568296964612,2.60299124232151,78.070398268207,percent_activity,1.30102999566398,20,,-0.272398259395052,-0.75526196068088,-0.722352916585617,20,cyp
NVS_ADME_hCYP2C9,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000762.2,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",https://www.ncbi.nlm.nih.gov/gene/1559,,,Active,25.9546345408837,1.297731727044185,7.88645112170019,0.896881616011544,2.17335298616219,25.9395837542938,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.962660947730422,0.837584438725882,0.777587752787803,20,cyp
NVS_ADME_hCYP2D6,"Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2D6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000097.3,CYP2D6,"cytochrome P450, family 2, subfamily D, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1565,,,Active,44.5957023949356,2.22978511974678,7.627943880583354,0.882407489245149,2.25000991599824,37.1630853310148,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.819102227959458,0.354769498235491,0.209925171239854,20,cyp
NVS_ENZ_hCASP5_Activator,"Data from the assay component NVS_ENZ_hCASP5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",NP_004338.3,CASP5,"caspase 5, apoptosis-related cysteine peptidase",https://www.ncbi.nlm.nih.gov/gene/838,,,Active,28.3962349798829,1.419811748994145,33.97538328238225,1.53116436478598,2.41734301604722,23.6635301416606,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only highest conc above baseline, active""]",1.62189017748087,1.41930950980242,1.30149071818278,20,protease
NVS_ENZ_oCOX1,"Data from the assay component NVS_ENZ_oCOX1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"".",NP_001009476.1,PTGS1,prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase),https://www.ncbi.nlm.nih.gov/gene/443551,"[177,28,100,101,63,102,103,28,63,100,101,177,102,103]",,Active,75.5056179764937,2.3978525426457367,9.80991048083373,0.991665044295614,5.24814159292036,62.9213483146067,percent_activity,1.69897000433602,31.4888495575222,,0.801177224211979,0.233057001253183,-0.257955985706366,20,oxidoreductase
NVS_ENZ_oCOX2,"Data from the assay component NVS_ENZ_oCOX2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"".",NP_001009432.1,PTGS2,prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase),https://www.ncbi.nlm.nih.gov/gene/443460,"[21,28,100,101,63,102,103,28,63,100,101,21,102,103]",,Active,22.1987326043535,1.109936630217675,11.206277353350714,1.04946136697495,0.893132530120482,21.8390804597701,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.40108923440263,0.733195766910894,0.699525916821727,20,oxidoreductase
NVS_ENZ_rCNOS,"Data from the assay component NVS_ENZ_rCNOS was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCNOS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""nitric oxide synthase"".",NP_434686.1,Nos1,"nitric oxide synthase 1, neuronal",https://www.ncbi.nlm.nih.gov/gene/24598,"[32,32]",,Active,56.4723791916042,2.2899250655459844,13.208803171660637,1.12086346867502,4.11020576184513,53.4555134637043,percent_activity,1.69897000433602,24.6612345710708,,1.07114678465648,0.871811304503327,0.691776546000258,20,oxidoreductase
NVS_GPCR_p5HT2C,"Data from the assay component NVS_GPCR_p5HT2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_p5HT2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2C. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000859.1,HTR2C,"5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled",https://www.ncbi.nlm.nih.gov/gene/3358,"[33,33]",[9],Active,26.5552375411321,1.1119004830188939,27.604842877722433,1.44098527954961,3.98045777577634,26.32796273121,percent_activity,1.69897000433602,23.882746654658,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.5598886429477,1.43002075203029,1.32169758354072,20,gpcr
NVS_NR_hPPARg,"Data from the assay component NVS_NR_hPPARg was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARg, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,"[34,36,58,72,163,72,36,58,34,163]",,Active,34.2127658797196,1.4127759041717654,30.304275491764766,1.48150390544915,4.03611615245008,28.5106382978723,percent_activity,1.69897000433602,24.2166969147005,"[""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.60206343317537,1.39949835631683,1.18213539533987,20,nuclear receptor
NVS_TR_hNET,"Data from the assay component NVS_TR_hNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",NP_001034.1,SLC6A2,"solute carrier family 6 (neurotransmitter transporter), member 2",https://www.ncbi.nlm.nih.gov/gene/6530,,,Active,64.4648317927256,2.481739330549844,18.661037673258498,1.27093578963772,4.32927765614309,53.7206931702345,percent_activity,1.69897000433602,25.9756659368585,,1.15113704477574,0.851376979078133,0.60152169972033,20,transporter
Tanguay_ZF_120hpf_ActivityScore,"Data from the assay component Tanguay_ZF_120hpf_ActivityScore was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_ActivityScore, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,87.8777029443856,4.39388514721928,16.009456536195536,1.20437658942477,2.2401450326604,83.8102947565914,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active"",""Noisy data""]",1.07602782427796,0.942712502453373,0.973593647098914,20,malformation
Tanguay_ZF_120hpf_AXIS_up,"Data from the assay component Tanguay_ZF_120hpf_AXIS_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_AXIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,118.908574435478,5.9454287217739,33.42187941254875,1.5240308679257,2.63537411808397,90.7804924995578,percent_activity,1.77815125038364,20,,1.17711081473718,0.950647021961642,1.0471596780316,20,malformation
Tanguay_ZF_120hpf_BRAI_up,"Data from the assay component Tanguay_ZF_120hpf_BRAI_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_BRAI_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,90.8920961176623,4.544604805883115,13.57783903995351,1.13283065597526,2.10016804911582,92.4865277570381,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.01936331649237,0.899946386485997,0.935811553986503,20,malformation
Tanguay_ZF_120hpf_CFIN_up,"Data from the assay component Tanguay_ZF_120hpf_CFIN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_CFIN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,90.5896623916606,4.52948311958303,16.575117522350354,1.21945661636051,2.13485958486518,90.358672839004,percent_activity,1.77815125038364,20,,1.10140978780974,0.978336348562509,1.01379107475011,20,malformation
Tanguay_ZF_120hpf_EYE_up,"Data from the assay component Tanguay_ZF_120hpf_EYE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_EYE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,121.592850521071,6.07964252605355,40.35989779445817,1.60595005777897,2.30241738279413,90.9354801811384,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.26349339793941,1.01393076783112,1.14296995790791,20,malformation
Tanguay_ZF_120hpf_JAW_up,"Data from the assay component Tanguay_ZF_120hpf_JAW_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_JAW_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,90.641514523107,4.53207572615535,10.778446663046214,1.03255617696615,2.62920060840169,90.6390079071476,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.934720883315078,0.850313365143857,0.862203103068539,20,malformation
Tanguay_ZF_120hpf_NC_up,"Data from the assay component Tanguay_ZF_120hpf_NC_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_NC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,82.1869716475096,4.10934858237548,46.45007888381217,1.66698645587057,1.76910974413219,86.3317051857951,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.60488662454738,1.52065326359137,1.54670641135584,20,malformation
Tanguay_ZF_120hpf_OTIC_up,"Data from the assay component Tanguay_ZF_120hpf_OTIC_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_OTIC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,86.8719724300653,4.343598621503265,9.319560778552743,0.969395444977826,1.97768058396892,90.4692818498563,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.902072446662348,0.823646746578896,0.846845398615309,20,malformation
Tanguay_ZF_120hpf_PE_up,"Data from the assay component Tanguay_ZF_120hpf_PE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,122.295050947109,6.11475254735545,34.88149670059171,1.54259511143434,2.88514919770174,92.1953253701594,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.19911489968898,1.00072148242115,1.08019100388833,20,malformation
Tanguay_ZF_120hpf_PFIN_up,"Data from the assay component Tanguay_ZF_120hpf_PFIN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PFIN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,90.7464828384911,4.537324141924556,9.428071799184922,0.974422881220878,2.18262089117193,90.7462356048654,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.896728181182639,0.817354664072877,0.83929807198703,20,malformation
Tanguay_ZF_120hpf_PIG_up,"Data from the assay component Tanguay_ZF_120hpf_PIG_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,120.9012457336,6.04506228668,38.15660127934891,1.58156968386853,1.93284296757538,91.0463116115357,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.17734560703017,0.835213233764528,1.03277730344078,20,malformation
Tanguay_ZF_120hpf_SNOU_up,"Data from the assay component Tanguay_ZF_120hpf_SNOU_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SNOU_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,120.904640767377,6.04523203836885,40.84121264626061,1.61109862856083,2.70483677373105,89.0823849229976,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.19019169043949,0.926629668024613,1.03966874206212,20,malformation
Tanguay_ZF_120hpf_SOMI_up,"Data from the assay component Tanguay_ZF_120hpf_SOMI_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SOMI_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,122.660765918185,6.13303829590925,42.15478020799819,1.62484682926313,1.97596700497027,92.6436081241935,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.29616360390803,1.02599068705023,1.1833283008949,20,malformation
Tanguay_ZF_120hpf_TRUN_up,"Data from the assay component Tanguay_ZF_120hpf_TRUN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TRUN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,90.5576725806367,4.527883629031836,11.565960086036462,1.06318168922609,2.21501896749265,90.5266144025363,percent_activity,1.77815125038364,20,,0.950445546272988,0.836412188443094,0.866697999983383,20,malformation
Tanguay_ZF_120hpf_TR_up,"Data from the assay component Tanguay_ZF_120hpf_TR_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,75.1283407352489,3.756417036762445,13.331213388885391,1.12486968010513,2.25069751143067,86.6261978680953,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.0436302105154,0.939370560107989,0.948820971845729,20,malformation
Tanguay_ZF_120hpf_YSE_up,"Data from the assay component Tanguay_ZF_120hpf_YSE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_YSE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,100.73777289521,5.0368886447605,11.495689240376135,1.06053501512843,3.19325001944697,100.732701772809,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.95935622041918,0.897185489061083,0.901225351626486,20,malformation
TOX21_AhR_LUC_Agonist,"Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001612.1,AHR,aryl hydrocarbon receptor,https://www.ncbi.nlm.nih.gov/gene/196,"[57,131,21,41,150,310,131,21,57,310,41,150]",[165],Active,47.7132034778513,2.385660173892565,31.610540324979706,1.49983191938123,1.20983399992497,31.9200787559,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.40893476397214,0.803982940343102,0.887521253125471,20,dna binding
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,24.1604716921048,1.20802358460524,32.30434616604623,1.50926095542566,2.57591984669775,24.2430359647,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.62372568101353,1.45425918754676,1.3490774660366,20,channel 1
TOX21_AP1_BLA_Agonist_ch2,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,56.7366269951837,2.662686204617464,30.980269706550004,1.49108519429977,3.55134017774949,56.7671335105,percent_activity,1.90308998699194,21.3080410664969,,1.45169093105028,1.37761368432902,1.32084095416428,20,channel 2
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1,"JUN | FOS|JUN","jun proto-oncogene , FBJ murine osteosarcoma viral oncogene homolog|jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/3725 , https://www.ncbi.nlm.nih.gov/gene/4029",,,Active,61.1778893716628,3.05889446858314,33.040447291487624,1.51904591803424,2.7369041511147,60.8320755447,percent_activity,1.90308998699194,20,,1.46267180025497,1.37351980193182,1.34752572340419,20,dna binding
TOX21_AR_BLA_Antagonist_ch2,"Data from the assay component TOX21_AR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,89.4472180459267,1.6940489402277963,39.7156599581561,1.59896178364996,8.80014108229746,87.0380843563,percent_activity,1.90308998699194,52.8008464937848,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.61878805229155,1.55170519539473,1.47968128606233,20,channel 2
TOX21_AR_BLA_Antagonist_ratio,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,90.7013078058525,3.4761525750532263,39.63570744033034,1.59808661413002,4.34874025461246,88.8233856058,percent_activity,1.90308998699194,26.0924415276748,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54886443845891,1.50125096471455,1.47880629925983,20,nuclear receptor
TOX21_AR_BLA_Antagonist_viability,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,47.7815426495049,2.072125990540759,40.616246422862076,1.60869978531295,3.8431979898606,47.0723062684,percent_activity,1.90308998699194,23.0591879391636,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.6049190565017,1.54651010474853,1.48941944734792,20,cell cycle
TOX21_ARE_BLA_Agonist_ch2,"Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,92.6789312018197,2.7410132674522134,126.52832580333595,2.10218776158291,5.63532060098133,38.3651116873,percent_activity,1.95424250943932,33.811923605888,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.85669083786905,1.43801174467895,1.12934068369713,20,channel 2
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,93.928009789733,4.69640048948665,99.76553290530047,1.99898052671355,2.50978290890691,45.0349205161,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.50258171401338,1.07246083244614,1.16470375213475,20,dna binding
TOX21_CASP3_CHO,"The assay component endpoint  TOX21_CASP3_CHO was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity following chemical treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.",NP_116786.1,CASP3,"caspase 3, apoptosis-related cysteine peptidase",https://www.ncbi.nlm.nih.gov/gene/836,,,Active,46.3422291693641,2.3171114584682053,106.63065082377983,2.02788205994634,0.87784491667383,23.8140328686,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",2.01271081101932,1.8731506674265,1.90685928196581,20,apoptosis
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,86.3111884609382,4.31555942304691,85.98479009845596,1.9344216354237,2.57636017956492,50.7092580418,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.86935202864163,1.80852214596191,1.81514131296666,20,cell cycle
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,80.9488933186673,3.3727836882060407,24.545024587987236,1.38996347149076,4.0001030208237,79.8230805698,percent_activity,1.69897000433602,24.0006181249422,,1.33524294848729,1.27923677621369,1.25081486285898,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,"RAD54L | XRCC6P1","RAD54 like (S. cerevisiae) , X-ray repair cross complementing 6 pseudogene 1","https://www.ncbi.nlm.nih.gov/gene/8438 , https://www.ncbi.nlm.nih.gov/gene/387703",,,Active,92.3078617603062,4.279576086007654,25.178669790613398,1.40103278225094,3.59489896137582,92.1138948298,percent_activity,1.69897000433602,21.5693937682549,,1.33655554605454,1.29122360821155,1.28175242726947,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,REV3L,"REV3 like, DNA directed polymerase zeta catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/5980,,,Active,85.5268759595628,3.2641335057106198,23.930600959179404,1.37895360500618,4.36700254498032,84.5671750889,percent_activity,1.69897000433602,26.2020152698819,,1.33458807498524,1.28612417005762,1.25966582718565,20,cell cycle
TOX21_ERb_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,54.9725311289911,2.2666712475314825,57.29921102918726,1.75814864207159,4.04208970819059,41.0018088185,percent_activity,1.95424250943932,24.2525382491435,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.71620141266439,1.53416659920013,1.36825672702943,20,nuclear receptor
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3,ESRRA,estrogen-related receptor alpha,https://www.ncbi.nlm.nih.gov/gene/2101,,,Active,33.4957111353518,1.585149256258195,45.76976876381429,1.66057871830772,3.52182515338437,34.6671448927,percent_activity,1.95424250943932,21.1309509203062,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.68967051492959,1.61851359798649,1.54129787655781,20,nuclear receptor
TOX21_HSE_BLA_agonist_ch2,"Data from the assay component TOX21_HSE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,56.3863072966317,2.819315364831585,43.223074503028364,1.63571565547203,0.96226530123801,23.416640401,percent_activity,1.47712125471966,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.47707552341171,0.861806483671767,1.05327431045157,20,channel 2
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,75.241556959331,1.946060936615398,29.410159610097026,1.46849738144676,6.44391923052108,60.9485642136,percent_activity,1.69897000433602,38.6635153831265,,1.48283062310991,1.19397559231152,0.90052049898841,20,cell morphology
TOX21_PGC_ERR_Antagonist,"Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",NP_004442.3,ESRRA,estrogen-related receptor alpha,https://www.ncbi.nlm.nih.gov/gene/2101,,,Active,111.579518790287,3.3466051729208703,284.6049883005835,2.45424250773854,5.55685104879492,47.999340755,percent_activity,1.95424250943932,33.3411062927695,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.65827756071161,0.831205473397516,0.40386042192906,20,nuclear receptor
TOX21_PPARg_BLA_Agonist_ch2,"Data from the assay component TOX21_PPARg_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,32.6437554418991,1.518606250910649,26.43646276658535,1.42220334552913,3.58264421980395,30.8805476757,percent_activity,1.90308998699194,21.4958653188237,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.56022416878948,1.27262727568288,0.960342298274124,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,63.3156646270458,3.16578323135229,71.64480420216809,1.85518470013255,2.51198214229767,38.2300128908,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.68942063408121,1.42580850295583,1.383873451944,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,,,Active,140.677106702952,7.033855335147599,208.01606282495848,2.3180968721113,1.80636679455099,32.8840383474,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.79651480641242,1.38448440111701,1.68048601482881,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_005051.2,RORC,RAR-related orphan receptor C,https://www.ncbi.nlm.nih.gov/gene/6097,,,Active,121.568366095395,2.3331308145314136,91.29942694450293,1.96046805162388,8.68420845631059,57.0068134108,percent_activity,1.95424250943932,52.1052507378635,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.94473192223308,1.88936613337947,1.84021698360039,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist_viability,"TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,84.5652423966066,4.2282621198303305,188.40609863002422,2.27509495662299,3.0881472477345,27.1666055878,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.84207501799949,1.50090282881933,1.46324550563289,20,cell cycle
TOX21_SHH_3T3_GLI3_Antagonist,"Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",,SHH,sonic hedgehog,https://www.ncbi.nlm.nih.gov/gene/6469,,,Active,135.254022827922,3.05989079398667,117.98076574802023,2.07181121060801,7.36703975915985,51.9860194824,percent_activity,1.95424250943932,44.2022385549591,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.87533223297532,1.62779154048716,1.47441736149651,20,dna binding
TOX21_SHH_3T3_GLI3_Antagonist_viability,"TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,95.4325728162161,4.771628640810805,99.35238341560166,1.99717829008527,2.48726544475101,30.6859179451,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.92511217431317,1.86324141052532,1.87789797616232,20,cell cycle